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Abstract
Background: The National Institute for Occupational Safety and Health previously reported mortality
for a cohort of workers considered highly exposed to polychlorinated biphenyls (PCBs) between 1939 and
1977 at two electrical capacitor manufacturing plants. The current study updated vital status, examined
liver and rectal cancer mortality previously reported in excess in this cohort and evaluated mortality from
non-Hodgkin's lymphoma (NHL) and cancers of the stomach, intestine, breast, prostate, skin (melanoma)
and brain reported to be in excess in other cohort and case-control studies of PCB-exposed persons.
Methods: Mortality was updated through 1998 for 2572 workers. Age-, gender-, race- and calendar year-
adjusted standardized mortality ratios (SMRs) and 95% confidence intervals (CI) were calculated using U.S.,
state and county referent rates. SMRs using U.S. referent rates are reported. Duration of employment was
used as a surrogate for exposure.
Results: Consistent with the previous follow-up, mortality from biliary passage, liver and gall bladder
cancer was significantly elevated (11 deaths, SMR 2.11, CI 1.05 – 3.77), but mortality from rectal cancer
was not (6 deaths, SMR 1.47, CI 0.54 – 3.21). Among women, mortality from intestinal cancer (24 deaths,
SMR 1.89, CI 1.21 – 2.82) and from "other diseases of the nervous system and sense organs", which include
Parkinson's disease and amyotrophic lateral sclerosis, (15 deaths, SMR 2.07, CI 1.16 – 3.42) were elevated.
There were four ALS deaths, all women (SMR 4.35, CI 1.19–11.14). Mortality was elevated for myeloma
(7 deaths, SMR 2.11, CI 0.84 – 4.34), particularly among workers employed 10 years or more (5 deaths,
SMR 2.80, CI 0.91 – 6.54). No linear associations between mortality and duration of employment were
observed for the cancers of interest.
Conclusion: This update found that the earlier reported excess in this cohort for biliary, liver and gall
bladder cancer persisted with longer follow-up. Excess mortality for intestinal cancer among women was
elevated across categories of duration of employment; myeloma mortality was highest among those
working 10 years or more. The small numbers of deaths from liver and intestinal cancers, myeloma and
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nervous system diseases coupled with the lack of an exposure-response relationship with duration of
employment preclude drawing definitive conclusions regarding PCB exposure and these causes of death.
Background
Polychlorinated biphenyls (PCBs) are synthetic chlorin-
ated aromatic hydrocarbons produced commercially in
the U.S. from 1929 to 1977 and used as electrical insulat-
ing and heat exchange fluids due to their high stability,
dielectric properties, resistance to oxidation, and incom-
bustibility [1,2]. Peak production of PCBs occurred in the
early 1970s. PCBs were banned in 1977 from U.S. produc-
tion and distribution because of concern about the per-
sistence of PCBs in the environment and potential health
risks [2]. PCBs remain a potential occupational exposure,
especially to persons who repair electrical equipment.
The purpose of this study was to update the mortality
experience of a cohort of electrical capacitor manufactur-
ing workers considered highly exposed to PCBs and to re-
examine the increased risks for mortality from cancers of
the liver and rectum previously observed in this cohort,
primarily among women employed in one plant [3,4].
These excesses had not been found to be related to dura-
tion of employment or time since first exposure in PCB-
exposed jobs. Other a priori outcomes of interest for which
previous studies indicated increased risks with respect to
PCB exposure included mortality from all cancers [5],
non-Hodgkin's lymphoma (NHL) [6], and breast [7], skin
(melanoma) and brain cancer [8]. Recent studies have
also associated PCB exposure with risk of prostate [9,10]
and stomach and intestinal cancer [11].
Methods
The study plants have been described previously [3,4].
Briefly, workers were employed for at least 90 days in elec-
trical capacitor manufacturing at a New York plant (Plant
1) between January 1, 1946, and June 30, 1977, or at a
Massachusetts plant (Plant 2) between January 1, 1939,
and March 29, 1976)[3,4]. The study cohort for this anal-
ysis was restricted to 2572 workers (Plant 1: 973; Plant 2:
1599) who held jobs identified as having the highest,
most direct exposure to PCBs (e.g., impregnation, sealing
and testing capacitors) and excluded workers confirmed at
the time of the original study to be solvent exposed [4].
PCBs at both plants included, at various times, Aroclor
1254 (54% chlorine), Aroclor 1242 (42% chlorine), and
Aroclor 1016 (41% chlorine) [4], with less chlorinated
varieties used more recently. At any given time, it is likely
that more than one Aroclor was in use. At Plant 1, use of
Aroclor 1254 was phased out in the 1950s and Aroclor
1016 was first used beginning in 1971[12]; at Plant 2, spe-
cific dates are not known. NIOSH conducted exposure
surveys at both plants in the spring of 1977. At Plant 1 the
time-weighted average (TWA) air samples ranged from 24
– 476 μg/m3. PCB levels were generally higher at Plant 2,
with TWAs from 50 – 1260 μg/m3 [4].
Vital status was updated through December 31, 1998.
Vital status was ascertained by linking with records of the
Social Security Administration, the Internal Revenue Serv-
ice, the National Death Index (NDI) [13], the U.S. Postal
Service and credit bureaus. Causes of death were obtained
from NDI Plus and from death certificates. A qualified
nosologist coded causes of death from death certificates
according to the International Classification of Diseases
(ICD) revision in effect at the time of death.
The mortality experience of the cohort was analyzed using
the NIOSH personal computer life-table analysis system
(PC-LTAS) [14,15]. Each cohort member accumulated
person-years at risk (PYAR) beginning on January 1, 1940,
or the date the worker achieved 90 days of potential PCB
exposure, whichever was later. Person time ended at the
date of death, the date the worker was lost to follow-up,
or the end date of the study (December 31, 1998), which-
ever was earliest. Person time was first stratified into gen-
der, race, 5-year age and 5-year calendar time strata and
then multiplied by the appropriate U.S. death rates to gen-
erate expected numbers of deaths for each stratum. The
resulting expected numbers of deaths were summed
across strata to generate the expected number of deaths for
each cause of death category and overall. NY county rates
were created by combining three counties (Washington,
Warren, and Saratoga), where 85% of Plant 1 workers
resided (as of last known address), and MA county rates
by combining two counties (Bristol and Plymouth),
where 89% of Plant 2 workers resided. The mortality anal-
ysis was repeated using these county death rates, death
rates from the state of New York (excluding New York
City) for Plant 1 and death rates for Massachusetts for
Plant 2. In addition to analyses using underlying cause of
death, "multiple cause" of death (MCOD) rates were also
used to examine non-cancer outcomes and cancers having
high survival rates (e.g., prostate and breast cancers) [16].
For myeloma, NHL and melanoma, U.S. rate files begin
on January 1, 1960, as do multiple cause, state and county
rate files. For other causes of death, U.S. rate files begin on
January 1, 1940.
The ratio of observed to expected number of deaths was
expressed as the standardized mortality ratio (SMR). SMR
95% confidence intervals (CI) were computed assuming a
Poisson distribution for the observed number of deaths.E
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Table 1: Vital status and demographic characteristics of PCB-exposed workers stratified by gender and plant a 
Characteristic Combined plants Plant 1 Plant 2
Total Men Women
Number of workers 2572 1247 (48) 1325 (52) 973 (38) 1599 (62)
Race, n (%)
White 2523 (98) 1239 (99) 1284 (97) 967 (99) 1556 (97)
Non-white 49 (2) 8 (1) 41 (3) 6 (1) 43 (3)
Vital status as of 12-31-1998, n (%)
Deceased, cause of death known 787 (31) 348 (28) 439 (33) 305 (31) 482 (30)
Deceased, cause of death unknown 11 (<1) 7 (1) 4 (<1) 5 (1) 6 (<1)
Alive 1743 (68) 876 (70) 867 (65) 655 (67) 1088 (68)
Unknown 31 (1) 16 (1) 15 (1) 8 (1) 23 (1)
Age at death or date last observed (years)
mean ± standard deviation 63.6 ± 13.0 59.8 ± 11.8 67.1 ± 13.2 64.1 ± 12.4 63.2 ± 13.4
median (range) 64.1 (18.5 – 102.0) 58.6 (19.5 – 95.4) 69.0 (18.5 – 102.0) 64.8 (27.4 – 95.4) 63.8 (18.5 – 102.0)
Time since last employment (years) b
median (range) 26.5 (0 – 52.6) 25.8 (0 – 51.8) 26.8 (0 – 52.6) 21.5 (0 – 52.6) 29.5 (0 – 49.0)
Age at first employment (years)
mean ± standard deviation 26.8 ± 10.2 25.1 ± 9.3 28.3 ± 10.7 29.0 ± 9.1 25.4 ± 10.5
median (range) 23.3 (15.0 – 63.7) 21.8 (15.2 – 63.7) 25.9 (15.0 – 63.7) 26.4 (17.1 – 57.2) 20.5 (15.0 – 63.7)
Duration of employment, n (%)
90 days – <5 years 1261 (49) 674 (54) 587 (44) 338 (35) 923 (58)
5 years – <10 years 448 (17) 205 (16) 243 (18) 201 (21) 247 (15)
≥10 years 863 (34) 368 (30) 495 (37) 434 (45) 429 (27)
median (range) 5.2 (0.3 – 35.8) 3.9 (0.3 – 35.8) 6.1 (0.3 – 35.1) 8.7 (0.3 – 31.4) 3.5 (0.3 – 35.8)
Time since first employment (years), n (%)
< 10 55 (2) 36 (3) 19 (1) 22 (2) 33 (2)
10 – <15 44 (2) 20 (2) 24 (2) 14 (1) 30 (2)
15 – <20 64 (2) 34 (3) 30 (2) 28 (3) 36 (2)
≥20 2409 (94) 1157 (93) 1252 (94) 909 (93) 1500 (94)
median (range) 36.8 (0.6 – 60.0) 33.3 (0.6 – 59.5) 39.6 (1.7 – 60.0) 33.1 (0.6 – 53.0) 38.5 (0.6 – 60.0)
Person-years at risk 93,623 42,826 50,797 33,834 59,789
a Number in parentheses indicates percent of total number of workers available for analysis.
b Employment refers to time worked during the time period when PCBs were in use at the plants.Environmental Health: A Global Access Science Source 2006, 5:13 http://www.ehjournal.net/content/5/1/13
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Statistical significance of the SMRs was computed using
exact methods for 5 or fewer deaths. For greater numbers
of observed deaths, the approximation method of Roth-
man and Boice [17] was used.
Duration of employment was used as a proxy for exposure
to evaluate whether mortality was associated with length
of exposure. Duration of employment was calculated,
using re-coded work histories, by considering all time
worked at the plant during the period of PCB use, not just
time spent in jobs with the highest, most direct exposure
to PCBs, as was done in the previous studies of this cohort
[3,4]. The list of the job codes designated in the previous
studies as having the highest and most direct PCB expo-
sure was not available for this update.
Results are presented overall and stratified by gender,
plant, duration of employment and time period of follow-
up. Three duration of employment groups (<5, 5–9 and ≥
10 years) were selected to allow comparisons with the pre-
vious update of this cohort [3]. For results stratified by
time period of follow-up (original time period through
1982 and updated time period 1983 – 1998), we consid-
ered causes of death considered important by Brown and
reported in his Table 3[3]. Trend tests were conducted for
selected outcomes using methods specified in Breslow et
al. [18], but only for those outcomes with at least 10
observed deaths.
There was some ambiguity as to the racial composition of
the Plant 2 cohort, for which race was not coded in com-
pany records. In LTAS analyses, workers of "unknown"
race are usually recoded 'white' for the analysis, and
white-race rate files are used. However, the Plant 2 cohort,
like the surrounding community, included many immi-
grants from the Cape Verde islands and the descendants of
those immigrants [4]. Most Cape Verdeans are considered
to be multiracial)[19] and therefore possibly 'non-white'.
However, because many death certificates that listed the
decedent's or decedent's parents' place of birth as Cape
Verde listed race as "white" and because many cohort
women, interviewed in 1997–2001 for an ancillary study,
identified themselves as "white", we did not change the
default LTAS recoding.
Results
The previous update examined the mortality experience of
2588 workers (Plant 1: 981; Plant 2: 1607). Work histo-
ries were recoded for the present update. Sixteen workers
(8 from each plant) were found to have worked fewer
than 90 days and were excluded. Gender was corrected for
34 workers. The present update included 2572 workers.
With 16 additional years of follow-up, 503 additional
deaths (Plant 1: 194; Plant 2: 309) and 38,078 additional
PYAR (Plant 1: 14,742; Plant 2: 23,336) were observed.
Cohort demographics and employment characteristics are
presented in Table 1. At Plant 1, more workers were male
(61%). At Plant 2, the proportion of male workers
increased over time from a minimum of around 10% in
the early 1940s to about 37% in 1976. Because turnover
was greater among men, men represent 41% of the total
number of workers ever employed at Plant 2.
Women and men worked in different jobs, especially at
Plant 1. At Plant 1, the top three job categories were: for
male workers, plant engineering craftsman, tool and die
maker, and treat room operator; for female workers,
assemble capacitors, tester, and check worker. At Plant 2,
the top three job categories were: for male workers, pre-
assembly, post-assembly, and oven and kettle operator;
for female workers, post-assembly, pre-assembly, and
electrical work.
SMRs are presented for all workers combined and strati-
fied by gender and plant in Table 2, for selected outcomes
stratified by duration of employment in Table 3, and for
selected outcomes stratified by time period of follow-up
(original time period through 1982 and update time
period 1983 – 1998) in Table 4. All tables present results
based on U.S. mortality rates since results were similar
using state and county rates, except as noted below. For
94% of the workers in this cohort, 20 years or more had
elapsed since first employment; therefore, results were not
stratified by time since first employment (TSFE) when
examining trends with duration of employment.
A priori causes of interest
Overall mortality was similar to expected (798 deaths,
SMR 0.99, CI 0.92 – 1.06) as was all cancer mortality (218
deaths, SMR 1.01, CI 0.88 – 1.15); however, cancer mor-
tality was significantly elevated in the update time period
(157 deaths, SMR 1.18, CI 1.00 – 1.38). Cancers of the bil-
iary passages, liver and gall bladder (henceforth referred
to as liver cancer) were significantly elevated in the cohort
(11 deaths, SMR 2.11, CI 1.05 – 3.77). Elevations in liver
cancer were observed for both genders and both plants.
The liver cancer elevation persisted across duration of
employment categories but did not increase with duration
of employment. Six new liver cancers were observed in the
updated time period. Mortality from rectal cancer
remained elevated in the cohort (6 deaths, SMR 1.47, CI
0.54 – 3.21), although only 2 new rectal cancers were
observed in the updated time period and the elevation
was somewhat reduced from the original study. The excess
was largely due to an excess of rectal cancer deaths among
women at Plant 2 in the original follow-up period. Mor-
tality from NHL was moderately elevated in the cohort
(10 deaths, SMR 1.31, CI 0.63 – 2.41), especially among
women at Plant 2, but the highest NHL mortality wasEnvironmental Health: A Global Access Science Source 2006, 5:13 http://www.ehjournal.net/content/5/1/13
Page 5 of 10
(page number not for citation purposes)
observed among workers with less than 10 years of
employment.
Results for other a priori outcomes were not remarkable.
Breast cancer was reduced in the cohort overall (15 deaths,
SMR 0.59, CI 0.33 – 0.98) and did not increase with dura-
tion of employment. Two deaths from skin cancer (one
malignant melanoma) and three deaths from brain cancer
were observed in the cohort.
Other cancer mortality
Prostate cancer was not elevated in the cohort (Table 2),
but a modest elevation was observed among workers with
10 years or more of employment (6 deaths, SMR 1.58, CI
0.58 – 3.44). Mortality from cancer of the intestine was
elevated, but only among women (24 deaths, SMR 1.89,
CI 1.21 – 2.82). The intestinal cancer elevation among
women persisted in each duration of employment cate-
gory but did not increase with duration of employment.
The excess was primarily due to intestinal cancer deaths
among women at Plant 2 in the updated time period.
Other cancer outcomes to note include myeloma and can-
cers of the kidney and female genital organs. Mortality
from myeloma was somewhat elevated (7 deaths, SMR
2.11, CI 0.84 – 4.34), and, although there were too few
deaths to test for a trend in mortality, the highest eleva-
tion was among workers employed for 10 years or more.
Mortality from kidney cancer was somewhat elevated (8
deaths, SMR 1.82, CI 0.79 – 3.60). Mortality from cancers
of the female genital organs was elevated in the time
period since the last update (14 deaths, SMR 1.85, CI
1.01–3.11).
Other causes of death
Other disease outcomes to note include diseases of the
nervous system and sense organs, ischemic heart disease,
and diseases of the digestive system. Mortality from other
diseases of the nervous system and sense organs, a cause
of death category that includes Parkinson's disease and
amyotrophic lateral sclerosis, was elevated, particularly
among women (15 deaths, SMR 2.07, CI 1.16 – 3.42).
There were four ALS deaths, all women (SMR 4.35, CI
1.19–11.14). In the multiple cause of death analysis,
which considered all causes listed on the death certificate,
an additional 23 deaths were observed for other diseases
of the nervous system and sense organs and an increasing
trend was observed with duration of employment. A more
detailed analysis can be found in Steenland et al[20] Mor-
tality from ischemic heart disease was elevated, particu-
larly among men (120 deaths, SMR 1.20, CI 0.99 – 1.43);
however, the elevation was limited to workers with less
than 10 years of employment. Mortality from diseases of
the digestive system was reduced, particularly among
Plant 1 workers (6 deaths, SMR 0.41, CI 0.15 – 0.89).
Mortality from accidents, primarily transportation acci-
dents, was elevated among Plant 1 workers, especially
when state rates were used (12 deaths, SMR 2.01, CI 1.04
– 3.51); however, mortality from accidents was reduced
among Plant 2 workers (13 deaths, SMR 0.53, CI 0.28 –
0.91). Mortality from suicide was elevated among Plant 1
workers, with the elevation even more pronounced when
state rates were used (11 deaths, SMR 2.79, CI 1.39–4.99).
Discussion
An additional 16 years of mortality experience has been
examined in this study, totalling 59 years of observation
time since 1940. The main goal of the study was to exam-
ine mortality from liver and rectal cancers previously
found to be in excess among workers exposed to PCBs.
Mortality patterns within this cohort corroborated other
studies showing excesses of liver cancer [21] and intestinal
cancer [5,11] among PCB-exposed workers, but this study
did not show that these excesses were related to duration
of employment. In contrast to other studies of PCB expo-
sure, only moderate excesses were found for NHL
[6,22,23] and prostate cancer [9,10], and none for cancers
of the skin [8,24], brain [8,25], or breast [26].
Results cannot confirm whether observed excesses in mor-
tality for liver and intestinal cancers, myeloma, and dis-
eases of the nervous system are related to PCB exposure
due to limited sample sizes, lack of exposure-response
with duration of employment, and lack of information on
potential confounders. Although data on smoking and
alcohol use are not available for this cohort, there is some
suggestion that these factors may not significantly contrib-
ute to the observed excesses of liver and intestinal cancers
or myeloma. Mortality from some diseases associated
with smoking and alcohol (cirrhosis of liver and respira-
tory diseases) was not elevated, although heart disease
mortality, particularly ischemic heart disease in men, did
not show a "healthy worker" effect [27]. Myeloma risk has
not been associated with smoking and alcohol use
[28,29], but it has been linked to occupational chemical
exposures [30,31]. It is also unlikely that regional differ-
ences contributed to the observed excesses in mortality
from intestinal and liver cancers or myeloma since state-
and county-based SMRs (not shown) were similar to
those using U.S. referent rates.
We cannot rule out the possibility that other factors,
including ethnic differences, may have contributed to the
observed excesses of intestinal and liver cancers and mye-
loma [32]. The ethnic make-up of the Plant 2 workforce
reflected that of the general population in the area, which
was largely Cape Verdean and Portuguese [4]. The Cape
Verde population was reported to be 71% Creole
(mulatto), 28% African, and 1% European [19]. Cape
Verde may share with other countries of West Africa a sub-Table 2: Observed deaths and SMRs for selected causes of deatha, stratified by gender and plant, 1940–1998.b
Underlying cause of death (ICD-9) Combined plants Plant 1 Plant 2
Total Men Women
O SMR 95% CI O SMR 95% CI O SMR 95% CI O SMR 95% CI O SMR 95% CI
All deaths 798 0.99 0.92 – 1.06 355 0.97 0.88 – 1.08 443 1.00 0.91 – 1.09 310 0.95 0.85 – 1.07 488 1.01 0.92 – 1.10
All cancers (140–208) 218 1.01 0.88 – 1.15 78 0.87 0.69 – 1.09 140 1.11 0.93 – 1.31 71 0.82 0.64 – 1.03 147 1.14 0.96 – 1.34
MN of buccal cavity and pharynx (140–149) 4 1.04 0.28 – 2.67 2 0.89 0.11 – 3.20 2 1.27 0.15 – 4.59 3 1.75 0.36 – 5.11 1 0.47 0.01 – 2.63
MN digestive system and peritoneum (150-159) 63 1.24 0.95 – 1.59 17 0.78 0.45 – 1.25 46 1.59 1.16 – 2.12 18 0.88 0.52 – 1.38 45 1.49 1.09 – 2.00
MN of esophagus (150) 2 0.55 0.07 – 2.00 0 2 1.67 0.20 – 6.03 0 2 1.03 0.12 – 3.72
MN of stomach (151) 5 0.84 0.27 – 1.97 4 1.35 0.37 – 3.45 1 0.34 0.01 – 1.87 0 5 1.46 0.47 – 3.40
MN of intestine, excluding rectum (152–153) 27 1.32 0.87 – 1.93 3 0.39 0.08 – 1.14 24 1.89 1.21 – 2.82 8 1.00 0.43 – 1.97 19 1.53 0.92 – 2.40
MN of rectum (154) 6 1.47 0.54 – 3.21 2 1.12 0.14 – 4.06 4 1.75 0.48 – 4.46 1 0.60 0.02 – 3.34 5 2.08 0.67 – 4.85
MN of biliary passages, liver and gall bladder (155–156) 11 2.11 1.05 – 3.77 4 1.86 0.51 – 4.77 7 2.28 0.92 – 4.69 4 1.92 0.52 – 4.92 7 2.23 0.90 – 4.59
MN of pancreas (157) 12 1.13 0.59 – 1.98 4 0.91 0.25 – 2.32 8 1.30 0.56 – 2.56 5 1.17 0.38 – 2.73 7 1.11 0.45 – 2.29
MN respiratory system (160–165) 60 1.03 0.79 – 1.33 30 0.90 0.61 – 1.28 30 1.21 0.82 – 1.73 25 0.95 0.62 – 1.41 35 1.10 0.76 – 1.53
MN of trachea, bronchus, and lung (162) 55 0.98 0.74 – 1.28 27 0.85 0.56 – 1.23 28 1.16 0.77 – 1.68 22 0.87 0.55 – 1.32 33 1.07 0.74 – 1.51
MN of breast (174–175) 15 0.59 0.33 – 0.98 0 15 0.60 0.33 – 0.98 2 0.27 0.03 – 0.97 13 0.73 0.39 – 1.25
MN of female genital organs (179–184) 21 1.29 0.80 – 1.97 21 1.29 0.80 – 1.97 5 1.07 0.35 – 2.50 16 1.38 0.79 – 2.24
MN of cervix uteri (180) 5 1.32 0.43 – 3.09 5 1.32 0.43 – 3.09 2 1.93 0.23 – 6.97 3 1.09 0.23 – 3.19
MN of other and unspecified parts of the uterus (179, 181, 
182)
7 1.87 0.75 – 3.84 7 1.87 0.75 – 3.84 3 2.82 0.58 – 8.25 4 1.49 0.41 – 3.80
MN of ovary, fallopian tube, and broad ligament (183) 9 1.10 0.50 – 2.08 9 1.10 0.50 – 2.08 0 9 1.56 0.71 – 2.96
MN of prostate (185) 7 1.14 0.46 – 2.35 7 1.14 0.46 – 2.35 5 1.39 0.45 – 3.25 2 0.79 0.10 – 2.85
MN urinary organs (188–189) 12 1.50 0.77 – 2.62 8 1.80 0.77 – 3.54 4 1.12 0.31 – 2.88 4 1.13 0.31 – 2.88 8 1.79 0.77 – 3.54
MN of kidney (189.0–189.2) 8 1.82 0.79 – 3.60 5 2.12 0.69 – 4.96 3 1.48 0.30 – 4.32 2 1.05 0.13 – 3.80 6 2.42 0.88 – 5.26
MN of bladder and other urinary organs (188, 189.3–189.9) 4 1.10 0.30 – 2.82 3 1.43 0.29 – 4.18 1 0.66 0.02 – 3.64 2 1.21 0.15 – 4.37 2 1.01 0.12 – 3.65
MN of skin (172–173) 2 0.52 0.06 – 1.87 2 0.92 0.11 – 3.33 0 1 0.61 0.02 – 3.39 1 0.45 0.01 – 2.50
Melanoma (173)c 1 0.34 0.01 – 1.87 1 0.60 0.02 – 3.35 0 1 0.80 0.02 – 4.45 0
MN of brain (191, 192) 3 0.50 0.10 – 1.47 2 0.70 0.08 – 2.53 1 0.32 0.01 – 1.80 2 0.82 0.10 – 2.96 1 0.28 0.01 – 1.58
MN of other and unspecified sites (194–199) 9 0.62 0.28 – 1.18 3 0.50 0.10 – 1.46 6 0.71 0.26 – 1.55 2 0.35 0.04 – 1.25 7 0.81 0.32 – 1.66
Neoplasms of lymphatic and hematopoietic tissue (200–208) 22 1.09 0.68 – 1.65 7 0.77 0.31 – 1.60 15 1.35 0.76 – 2.23 4 0.49 0.13 – 1.26 18 1.50 0.89 – 2.37
Leukemia and aleukemia (204–208) 4 0.53 0.14 – 1.36 2 0.57 0.07 – 2.07 2 0.50 0.06 – 1.79 0 4 0.90 0.24 – 2.29
Non-Hodgkin's lymphoma (200, 202)c 10 1.31 0.63 – 2.41 2 0.60 0.07 – 2.18 8 1.86 0.80 – 3.66 1 0.32 0.01 – 1.80 9 1.98 0.91 – 3.77
Myeloma (203)c 7 2.11 0.84 – 4.34 3 2.22 0.46 – 6.50 4 2.03 0.55 – 5.19 3 2.25 0.46 – 6.59 4 2.01 0.55 – 5.14
Diabetes mellitus (250) 16 0.88 0.50 – 1.43 4 0.63 0.17 – 1.61 12 1.02 0.53 – 1.78 5 0.73 0.24 – 1.72 11 0.97 0.48 – 1.74
Diseases of the nervous system and sense organs (320–389) 18 1.37 0.81 – 2.17 2 0.40 0.05 – 1.44 16 1.97 1.13 – 3.20 9 1.78 0.81 – 3.38 9 1.12 0.51 – 2.12
Other diseases of the nervous system and sense organs 
(320–337, 341–389)
16 1.35 0.77 – 2.19 1 0.22 0.01 – 1.21 15 2.07 1.16 – 3.42 8 1.75 0.75 – 3.44 8 1.10 0.47 – 2.17
Diseases of the heart (390–398, 402, 404, 410–414, 420–429) 286 1.06 0.94 – 1.19 150 1.17 0.99 – 1.38 136 0.96 0.81 – 1.14 120 1.08 0.89 – 1.29 166 1.05 0.90 – 1.22
Ischemic heart disease (410–414) 224 1.12 0.98 – 1.28 120 1.20 0.99 – 1.43 104 1.04 0.85 – 1.26 93 1.10 0.88 – 1.34 131 1.14 0.95 – 1.35
Hypertension with heart disease (402, 404) 4 0.46 0.13 – 1.18 1 0.33 0.01 – 1.85 3 0.53 0.11 – 1.55 1 0.32 0.01 – 1.77 3 0.54 0.11 – 1.59
Other diseases of the heart (420–423, 425–428, 429.2–
429.9)
42 0.87 0.62 – 1.17 20 0.98 0.60 – 1.51 22 0.79 0.49 – 1.19 20 1.06 0.65 – 1.64 22 0.74 0.47 – 1.13
Other diseases of the circulatory system (401, 403, 405, 415–
417, 430–459)
82 1.07 0.85 – 1.33 27 1.03 0.68 – 1.49 55 1.10 0.83 – 1.43 29 1.02 0.68 – 1.46 53 1.10 0.83 – 1.44
Diseases of the respiratory system (460–519) 46 0.79 0.58 – 1.05 19 0.76 0.46 – 1.19 27 0.81 0.53 – 1.18 21 0.88 0.54 – 1.34 25 0.73 0.47 – 1.07
Chronic and unspecified bronchitis (490, 491) 3 1.97 0.41 – 5.76 1 1.43 0.04 – 7.97 2 2.42 0.29 – 8.74 1 1.54 0.04 – 8.56 2 2.29 0.28 – 8.26
Emphysema (492) 8 1.15 0.50 – 2.28 4 1.10 0.30 – 2.81 4 1.22 0.33 – 3.11 5 1.59 0.51 – 3.71 3 0.79 0.16 – 2.32
Pneumoconiosis and other respiratory diseases (470–478, 
494–519)
20 0.74 0.45 – 1.14 9 0.74 0.34 – 1.41 11 0.73 0.37 – 1.31 10 0.87 0.42 – 1.61 10 0.64 0.31 – 1.18
Diseases of the digestive system (520–579) 29 0.80 0.54 – 1.15 14 0.82 0.45 – 1.38 15 0.78 0.44 – 1.29 6 0.41 0.15 – 0.89 23 1.07 0.68 – 1.60
Cirrhosis of the liver (571) 17 1.02 0.59 – 1.63 10 1.06 0.51 – 1.95 7 0.96 0.39 – 1.99 4 0.56 0.15 – 1.42 13 1.37 0.73 – 2.34Diseases of the genitourinary system (580–629) 13 1.04 0.55 – 1.78 5 1.15 0.37 – 2.69 8 0.98 0.42 – 1.93 2 0.43 0.05 – 1.56 11 1.39 0.69 – 2.49
Accidents (E800-E949) 31 0.75 0.51 – 1.06 19 0.67 0.40 – 1.05 12 0.91 0.47 – 1.60 18 1.07 0.63 – 1.69 13 0.53 0.28 – 0.91
Suicide (E950-E959) 20 1.37 0.83 – 2.11 14 1.36 0.74 – 2.28 6 1.39 0.51 – 3.02 12 1.90 0.98 – 3.32 8 0.96 0.41 – 1.90
Homicide (E960-E978) 4 0.74 0.20 – 1.90 4 1.00 0.27 – 2.56 0 2 0.95 0.11 – 3.42 2 0.61 0.07 – 2.21
Unknown cause of death 11 7 4 5 6
Other 8 0.40 0.17 – 0.79 5 0.55 0.18 – 1.28 3 0.28 0.06 – 0.81 1 0.14 0.00 – 0.75 7 0.56 0.22 – 1.15
Abbreviations: ICD-9: International Classification of Diseases, Ninth Revision; O: observed number of deaths; SMR: standardized mortality ratio based on U.S. referent rates; CI: confidence interval; MN: malignant neoplasm.
a Categories omitted from the table include tuberculosis (ICD-9 = 010–018, 2 deaths), benign and unspecified neoplasms (ICD-9 = 210–239, 2 deaths), diseases of the blood and blood forming organs (ICD-9 = 280–289, 4 deaths), 
mental, psychoneurotic, and personality disorders (ICD-9 = 290–319, 2 deaths), diseases of the skin and subcutaneous tissue (ICD-9 = 680–709, 1 death), musculoskeletal diseases (ICD-9 = 710–739, 1 death), and symptoms and 
ill-defined conditions (ICD-9 = 780–796, 798, 799, 4 deaths).
b Person-years at risk and observed deaths among 2572 workers in jobs with potential for the highest, most direct exposure to PCBs began accruing in 1940.
c Person-years at risk and observed deaths began accruing in 1960 for melanoma, non-Hodgkin's lymphoma and myeloma due to rate file restrictions.
Table 2: Observed deaths and SMRs for selected causes of deatha, stratified by gender and plant, 1940–1998.b (Continued)
Table 3: Observed deaths and SMRs for selected causes of deatha, stratified by duration of employmentb
Cause of death Duration of employment Trend p-
valuec
< 5 years 5 – 9 years ≥10 years
O SMR 95% CI O SMR 95% CI O SMR 95% CI
All deaths 279 1.07 0.95 – 1.21 148 1.07 0.90 – 1.25 371 0.90 0.81 – 1.00 0.018
All cancers 73 1.08 0.84 – 1.35 41 1.06 0.76 – 1.44 104 0.95 0.78 – 1.15 0.38
MN of intestine, excluding rectum 7 1.16 0.47 – 2.39 6 1.69 0.62 – 3.67 14 1.30 0.71 – 2.17 0.97
Among women 7 1.94 0.78 – 4.00 6 2.46 0.90 – 5.36 11 1.66 0.83 – 2.97 0.61
MN of rectum 0 2 2.75 0.33 – 9.93 4 1.91 0.52 – 4.89 ---
MN of biliary passages, liver and gall bladder 4 2.49 0.68 – 6.38 2 2.16 0.26 – 7.80 5 1.86 0.60 – 4.34 0.66
MN of breast 5 0.61 0.20 – 1.43 2 0.39 0.05 – 1.40 8 0.67 0.29 – 1.32 0.74
MN of prostate 1 0.64 0.02 – 3.55 0 6 1.58 0.58 – 3.44 ---
Neoplasms of lymphatic and hematopoietic tissue 9 1.33 0.61 – 2.52 3 0.84 0.17 – 2.47 10 1.02 0.49 – 1.88 0.65
Non-Hodgkin's lymphomad 4 1.63 0.44 – 4.16 3 2.32 0.48 – 6.78 3 0.78 0.16 – 2.27 0.25
Myelomad 2 2.08 0.25 – 7.50 0 5 2.80 0.91 – 6.54 ---
Other diseases of the nervous system and sense organs
Underlying cause of death 1 0.27 0.01 – 1.48 3 1.56 0.32 – 4.56 12 1.95 1.01–3.40 0.039
Multiple cause of deathd 6 0.51 0.19 – 1.10 4 0.65 0.18 – 1.66 28 1.37 0.91–1.98 0.011
Ischemic heart disease 69 1.22 0.95 – 1.54 47 1.44 1.06 – 1.91 108 0.97 0.80 – 1.18 0.057
Abbreviations: O: observed number of deaths; SMR: standardized mortality ratio; CI: confidence interval; MN: malignant neoplasm.
a A priori causes of death with sufficient numbers to stratify plus significant new findings.
b Person-years at risk and observed deaths among 2572 workers in jobs with potential for the highest, most direct exposure to PCBs began accruing in 1940.
c Trend test performed for causes of death with 10 or more observed deaths.
d Person-years at risk and observed deaths began accruing in 1960 for non-Hodgkin's lymphoma, myeloma, and multiple cause of death from other diseases of the nervous system and sense organs due to rate file restrictions.Environmental Health: A Global Access Science Source 2006, 5:13 http://www.ehjournal.net/content/5/1/13
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stantial risk of liver cancer, due in large part to hepatitis
infection [33]. First-generation emigrants from West
Africa retain an increased risk of liver cancer [34]. If most
of the Cape Verdean workers at Plant 2 were born in the
United States, their baseline rates of liver cancer (absent
exposure) would be similar to those in the U.S., as liver
and intestinal cancer rates in the offspring of immigrants
are closer to those in their parents' adopted country than
in their ancestral country [35]. It is unlikely that ethnic
differences account for our results because additional liver
cancer deaths have occurred among Plant 1 workers and
males during the update period, suggesting that any initial
differences in risk by plant and gender may have dimin-
ished over time with increased follow-up and latency
(Table 4). Exposure to PCBs appears to have been higher
in Plant 2 than Plant 1 [3,4] and both plants used the
same Aroclor formulations. If PCBs have a causal relation-
ship with liver cancer one would expect more cancer in a
more highly exposed population.
In the current update, new findings include observed
excesses of myeloma and diseases of the nervous system
among women, neither of which has been reported in
other studies of PCB-exposed workers. Associations have
been reported between PCB exposure and Parkinson's or
other neuropathology [36,37] and between dioxin, struc-
turally similar to some PCB congeners, and myeloma
[38]. Although based on small numbers of deaths, SMRs
for myeloma were consistently elevated among men and
women at both plants. The excess in mortality from dis-
eases of the nervous system requires further exploration in
other PCB-exposed cohorts, in light of the fourfold excess
in ALS mortality as well as excess Parkinson's and demen-
tia deaths in this highly exposed cohort. Our separate
mortality analysis of neurodegenerative disease mortality
among a large (n = 17,247) cohort of PCB-exposed work-
ers which included all the workers in this study as well as
other workers at these plants and workers at a third capac-
itor manufacturing plant found additional excess deaths
among the workers with relatively higher cumulative
exposure [20].
This study cannot fully evaluate any association between
PCB exposure and breast cancer, a subject of ongoing
interest in the environmental exposure literature [39,40],
absent data on generally acknowledged breast cancer risk
factors, such as parity and ages at menarche, first birth,
and menopause. We have initiated a study of breast cancer
among women occupationally exposed to PCBs with an
interview component to obtain information on known
risk factors.
Study limitations include the small cohort size and low
number of deaths, lack of data on potential confounders
and possible misclassification of exposure due to use of
duration of employment as a surrogate for cumulative
PCB exposure. Internal analyses using an internal referent
group were not performed, since the cohort, by definition,
included only workers who were highly exposed. Given
these limitations, we will explore exposure-response rela-
tionships in an expanded cohort of workers at these plants
with a wider range of potential PCB exposures. These anal-
yses, which will be reported elsewhere, will use newly cre-
ated job exposure matrices developed to estimate
cumulative exposure to PCBs for workers at the two
plants.
Conclusion
Our results are consistent with previous studies of this
cohort which also reported significantly elevated mortal-
ity from liver cancers, which was not found to be associ-
ated with duration of employment. In this update, the
SMR for rectal cancer was elevated but lower than that
observed in the last update and was not related to dura-
tion of employment. Increased mortality was also
observed for myeloma and intestinal cancer (among
women), but these elevations were not associated with
duration of employment in a linear fashion. Mortality
from diseases of the nervous system was associated with
duration of employment. NHL and prostate cancer mor-
tality were only moderately elevated. There was no evi-
dence of increased mortality risk from cancers of the
breast, skin or brain due to PCB exposure in this cohort.
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Roberts for assistance with data collection and/or preparation.Table 4: Observed number of deaths and SMRs for selected cancers, stratified by plant, gender and study periods.
Underlying cause of death Combined plants Plant 1 Plant 2
Total Men Women
O SMR 95% CI O SMR 95% CI O SMR 95% CI O SMR 95% CI O SMR 95% CI
All cancers (1940 – 1982) a 62 0.78 0.60 – 1.00 17 0.54 0.32 – 0.87 45 0.93 0.68 – 1.25 18 0.58 0.34 – 0.91 44 0.91 0.66 – 1.22
All cancers (1983 – 1998) b 157 1.18 1.00 – 1.38 61 1.04 0.80 – 1.34 96 1.29 1.05 – 1.58 53 0.97 0.73 – 1.27 104 1.33 1.08 – 1.61
MN of stomach (1940 – 1982) 1 0.36 0.01 – 1.99 1 0.71 0.02 – 3.98 0 0 1 0.63 0.02 – 3.48
MN of stomach (1983 – 1998) 4 1.26 0.34 – 3.23 3 1.82 0.37 – 5.31 1 0.66 0.02 – 3.67 0 4 2.19 0.60 – 5.60
MN of intestine, excluding rectum (1940 – 1982) 8 1.04 0.45 – 2.05 1 0.38 0.01 – 2.14 7 1.37 0.55 – 2.83 3 1.03 0.21 – 3.02 5 1.04 0.34 – 2.43
MN of intestine, excluding rectum (1983 – 1998) 19 1.51 0.91 – 2.36 2 0.39 0.05 – 1.42 17 2.27 1.32 – 3.64 5 0.99 0.32 – 2.32 14 1.86 1.02 – 3.12
MN of rectum (1940 – 1982) 4 2.11 0.57 – 5.39 1 1.25 0.03 – 6.96 3 2.73 0.56 – 7.97 1 1.25 0.03 – 6.96 3 2.73 0.56 – 7.97
MN of rectum (1983 – 1998) 2 0.94 0.11 – 3.40 1 1.02 0.03 – 5.65 1 0.88 0.02 – 4.87 0 2 1.60 0.19 – 5.78
MN of biliary passages, liver and gall bladder (1940 – 1982) 5 2.63 0.85 – 6.14 1 1.43 0.04 – 7.96 4 3.33 0.91 – 8.53 1 1.43 0.04 – 7.96 4 3.33 0.91 – 8.53
MN of biliary passages, liver and gall bladder (1983 – 1998) 6 1.82 0.67 – 3.97 3 2.04 0.42 – 5.97 3 1.65 0.34 – 4.81 3 2.22 0.46 – 6.50 3 1.54 0.32 – 4.51
MN of pancreas (1940 – 1982) 2 0.54 0.07 – 1.95 1 0.63 0.02 – 3.48 1 0.48 0.01 – 2.65 1 0.67 0.02 – 3.71 1 0.45 0.01 – 2.53
MN of pancreas (1983 – 1998) 10 1.46 0.70 – 2.69 3 1.06 0.22 – 3.11 7 1.74 0.70 – 3.58 4 1.45 0.39 – 3.71 6 1.47 0.54 – 3.19
MN of respiratory system (1940 – 1982) 10 0.59 0.28 – 1.09 5 0.45 0.15 – 1.05 5 0.86 0.28 – 2.01 7 0.88 0.35 – 1.80 3 0.34 0.07 – 0.99
MN of respiratory system (1983 – 1998) 50 1.23 0.92 – 1.63 25 1.12 0.72 – 1.65 25 1.38 0.89 – 2.04 18 1.01 0.60 – 1.59 32 1.41 0.97 – 1.99
MN of urinary organs (1940 – 1982) 4 1.43 0.39 – 3.66 4 2.50 0.68 – 6.40 0 2 1.67 0.20 – 6.02 2 1.25 0.15 – 4.52
MN of urinary organs (1983 – 1998) 8 1.52 0.66 – 3.00 4 1.35 0.37 – 3.46 4 1.74 0.48 – 4.46 2 0.86 0.10 – 3.11 6 2.05 0.75 – 4.45
Neoplasms of lymphatic and hematopoietic tissues (1940 – 1982) 5 0.68 0.22 – 1.58 1 0.29 0.01 – 1.64 4 1.00 0.27 – 2.56 0 5 1.11 0.36 – 2.59
Neoplasms of lymphatic and hematopoietic tissues (1983 – 1998) 17 1.38 0.80 – 2.20 6 1.08 0.40 – 2.36 11 1.61 0.80 – 2.88 4 0.79 0.22 – 2.02 13 1.78 0.95 – 3.05
MN of breast (1940 – 1982) 9 0.77 0.35 – 1.46 0 9 0.77 0.35 – 1.46 1 0.30 0.01 – 1.69 8 0.96 0.42 – 1.90
MN of breast (1983 – 1998) 6 0.46 0.17 – 1.01 0 6 0.46 0.17 – 1.01 1 0.25 0.01 – 1.41 5 0.55 0.18 – 1.29
MN of female genital organs (1940 – 1982) 7 0.85 0.34 – 1.76 7 0.85 0.34 – 1.76 1 0.43 0.01 – 2.42 6 1.02 0.37 – 2.21
MN of female genital organs (1983 – 1998) 14 1.85 1.01 – 3.11 14 1.85 1.01 – 3.11 4 1.74 0.47 – 4.44 10 1.91 0.91 – 3.50
Abbreviations: O: observed number of deaths; SMR: standardized mortality ratio based on U.S. referent rates; CI: confidence interval; MN: malignant neoplasm.
a Results for vital status follow-up from 1940 through 1982 based on 2588 workers in jobs with the potential for the highest, most direct exposure to PCBs and computed from observed and expected deaths reported in 
Table 3 of Brown (1987).
b Results for vital status follow-up from 1983 through 1998 based on 2257 PCB exposed workers (current cohort of 2572 workers [2588 workers less 16 with < 90 days of employment based on the recoded work histories] 
in jobs with the potential for the highest, most direct exposure to PCBs less 291 workers who died and 24 workers lost to follow-up prior to 1983).Publish with BioMed Central    and   every 
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